Although no commission based financial advisor would ever agree with this, I believe the "safest" investment advice would be to pay off your mortgage first. The concept here of course is that the rate of return equals the interest rate on the loan.
With regards to the equity market, I believe the next boom sector will be healthcare, and more specifically, Wireless Healthcare, so based on this assumption Qualcomm could be the next Apple, Imo!
Executive Vice President is Donald Rosenberg who was the Senior VP, General Counsel and Corporate Secretary for Apple until 2007, and Senior VP and General Counsel at IBM Corp before Apple
If you are looking for a couple of de-risked micro-cap opportunities in regards to your reference of Ceramic Fuel Cells, which I would also agree, is one good proposition, you might also be interested proceeding due diligence on one of the following:
TIS - Tissue Therapies have developed the world's most clinically effective technology for acute and chronic wound healing applications with CE Mark expected to be received next month for commencing European sales which is conservatively estimated to attract +$1b dollars in revenue for the first 12 months.
MCap: $81,223,264
* Tissue Therapies CEO, Dr Steven Mercer is the former General Manager of $8.8b dollar Smith & Nephew
* Tissue Therapies Chairman, Mr Roger Clarke is also Chairman of the Board of Advice of RBS Morgans
* Tissue Therapies Director, Dr Cherrell Hirst is also a Director of Medibank Private Limited
* Tissue Therapies Clinical Advisor to the Board, Prof. Keith Harding is considered the world's foremost authority on Wound Healing ___
QRX - Developing innovative products for pain management and CNS disorders.
MCap: $245,649,500
* QRxPharma Chairman, Peter Farrell founded ResMed Inc in 1989 which trades on both the ASX: RMD and NYSE: RMD with a MCap of $4.4b dollars.
* QRxPharma Managing Director & CEO, Dr Holaday founded Medicis Pharmaceutical Corp in 1988 which trades on the NYSE with a MCap of $2.3b dollars. ___
SPL - Nanotechnology in pharmaceutical applications
MCap: $457,659,095
* StarPharma Chairman, Peter Bartels is former CEO and Managing Director of both Coles Myer Ltd and Fosters Brewing Company Ltd
* Starpharma Director, Mr Richard Hazleton is former chairman and CEO of $40b dollar Dow Corning Corporation in the US
* StarPharma Director, Ms Zita Peach is former Vice President/Director of $20b dollar CSL Limited in Australia ___
ACR - Specialises in Transdermal Drug Delivery Technology and in March 2010, signed the largest single product licensing deal in the history of Australian biotechnology with Lilly
MCap: $660,991,943
* Acrux Deputy Chairman, Mr Ken Windle is former CEO of GlaxoSmithKline
* Acrux CFO, Mr Jon Pilcher has held former Senior Management positions with ANZ Bank ___
Imo, the best investment you could ever give a child is unconditional love
